2026-06-14T03:39:13Zhttps://repisalud.isciii.es/rest/oai/requestoai:repisalud.isciii.es:20.500.12105/203812024-11-28T23:05:02Zcom_20.500.12105_15322com_20.500.12105_2051col_20.500.12105_16967col_20.500.12105_16968
Repisalud
author
Martinez-Lopez, J
author
Sanchez-Vega, B
author
Barrio, S
author
Cuenca, I
author
Ruiz-Heredia, Y
author
Alonso, R
author
Rapado, I
author
Marin, C
author
Cedena, M-T
author
Paiva, B
author
Puig, N
author
Mateos, M-V
author
Ayala, R
author
Hernandez, M-T
author
Jimenez, C
author
Rosinol, L
author
Martinez, R
author
Teruel, Ana Isabel
author
Gutierrez, N
author
Martin-Ramos, Maria-Luisa
author
Oriol, A
author
Bargay Lleonart, Joan
author
Blade, J
author
San-Miguel, J
author
Garcia-Sanz, R
author
Lahuerta, J-J
2024-07-11T09:07:19Z
2024-07-11T09:07:19Z
2017-06
Martinez-Lopez J, Sanchez-Vega B, Barrio S, Cuenca I, Ruiz-Heredia Y, Alonso R, et al. Analytical and clinical validation of a novel in-house deep-sequencing method for minimal residual disease monitoring in a phase II trial for multiple myeloma [letter]. Leukemia. 2017 Jun;31(6):1446-9. Epub 2017 Feb 17.
10.1038/leu.2017.58
1476-5551
0887-6924
Leukemia
http://hdl.handle.net/20.500.13003/10944
28210002
L614736600
2-s2.0-85014659967
http://hdl.handle.net/20.500.12105/20381
402832700025
eng
Analytical and clinical validation of a novel in-house deep-sequencing method for minimal residual disease monitoring in a phase II trial for multiple myeloma
letter to the editor